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High expression of Epidermal Growth Factor Receptor (EGFR) is common in many human ma-
lignancies, such as glioblastoma multiforme (GBM) and head-neck squamous cell carcinomas 
(HNSCC), and is associated with worse outcome441. EGFR signalling is involved in several path-
ways, such as PI3K and MAPK, leading to increased proliferation and loss of apoptosis442. Be-
cause of its high prevalence and important role in cancer, several EGFR-targeted drugs such 
as monoclonal antibodies and tyrosine-kinase inhibitors have been developed. These targeted 
agents are considered standard in the treatment of several tumour types443.
In HNSCC anti-EGFR monoclonal antibodies are routinely used for several years14,15. The benefit 
of the addition of cetuximab to radiotherapy in the curative setting has been shown in one ran-
domized controlled trial (RCT)92. Moreover, in the recurrent/metastatic setting, overall survival 
significantly improved with the addition of cetuximab to chemotherapy99. However, trials show 
low response rates of 10-16% attributed to cetuximab, irrespective of use as single agent or in 
combination with another modality96-99. These results illustrate that, despite EGFR expression in 
>95% of included patients96-99 only a small group of patients will benefit from therapy targeting 
the EGFR molecule. Despite many efforts, EGFR gene amplification444 and EGFR protein expres-
sion level445 do not accurately identify patients who will benefit from EGFR-targeted therapy.
More recently, expression of a specific mutant form of EGFR, called EGFR variant III (EGFRvIII) 
was found to be expressed in GBM. EGFRvIII is not readily distinguished from normal EGFR, and 
might be responsible for the lack of effect of EGFR-targeted therapy.
EGFRvIII is a specific variant of EGFR, that harbours a deletion of exons 2-7, encoding the ex-
tracellular ligand-binding domain. It is the most common and best described EGFR mutation in 
various malignancies441. The EGFRvIII protein is present in 20-30% of unselected GBM, and in 
comparable rates in breast carcinoma, while not being expressed in normal tissues (reviewed 
in446). The truncated protein is constitutively active103 and, unlike EGFR, does not need dimeriza-
tion to link to downstream targets447. Moreover, degradation of EGFRvIII is slow because of im-
paired internalization and sorting to lysozomes448. EGFRvIII has been associated with increased 
tumour cell proliferation in a mouse model104, lower response to carboplatin104 and radioresist-
ance through increased double-strand break repair449 in vitro. Because of loss of the extracellular 
ligand-binding domain anti-EGFR monoclonal antibodies do not affect EGFRvIII. Moreover, EG-
FRvIII is relatively resistant to tyrosine kinase inhibitors450. Therefore, EGFRvIII might account 
for the lack of response to monoclonal antibody therapy in HNSCC. Also, EGFRvIII-associated 
radioresistance could be relevant in HNSCC, which are frequently treated by radiotherapy14,15. 
Therefore, it is important to know the prevalence of EGFRvIII in HNSCC.
Although EGFR expression is ubiquitous in HNSCC, expression of EGFRvIII has been reported 
at rates varying from 0-80%104,451-458. All studies have been performed in small patient groups 
(n<50), selected with unclear criteria, and using a single detection technique in nearly all cases. 
Therefore, the exact prevalence of EGFRvIII in a representative group of HNSCC remains to be 
determined.
Abstract
Introduction: EGFRvIII is a specific variant of EGFR, and is the most common EGFR mutation in 
glioblastoma and several other tumour types. The truncated EGFRvIII protein is constitutively 
active and degradation is impaired. Expression has been associated with increased tumour cell 
proliferation and resistance to chemotherapy and irradiation in vitro. Expression of EGFRvIII is 
reported in HNSCC and not readily distinguished from normal EGFR, and might be responsible 
for the lack of effect of EGFR-targeted therapy. Because EGFR-targeted therapy is an accepted 
treatment modality in HNSCC, it is important to assess the prevalence of this mutation in HN-
SCC.
Methods: Immunohistochemistry for the specific detection of EGFRvIII using the L8A4 anti-
body was optimized on formalin-fixed, paraffin-embedded (FFPE) tissue using glioblastoma 
tissue. It was compared to EGFR and EGFRvIII RNA expression using a specific rt-PCR also opti-
mized for FFPE tissue. Tissue microarrays including 531 HNSCC of various stages with complete 
clinicopathological and follow-up data were tested for the presence of EGFRvIII.
Results: None of the 531 cases showed EGFRvIII protein expression. Using an immunohisto-
chemistry protocol reported by others revealed cytoplasmic staining in 8% of cases. rt-PCR for 
the EGFRvIII transcript of the 28 highest cytoplasmic staining cases, as well as 67 negative 
cases did not show expression in any of the tested cases, suggesting aspecific staining by a 
non-optimal protocol.
Conclusions: The EGFRvIII mutation is not present in HNSCC. Therefore, EGFRvIII does not 








proper secondary use of human tissue in the Netherlands301, as well as to the relevant institu-
tional and national guidelines. In total 30/552 (5%) cases were not assessable because no core 
with a representative amount of tumour cells was present. For the current study, only cases for 
which EGFRvIII expression could be assessed were analyzed, including 189 OSCC patients, 184 
OpSCC patients and 149 POSTOP patients (total n=522; table 9.1).
Population characteristics
Median age at diagnosis of the 522 patients was 60 years, of which 63% were male. Half of tu-
mours (52%) were located in the oral cavity. Patient and tumour characteristics are presented in 
table 9.1. HPV status, assessed with a triple algorithm of p16 immunohistochemistry, HPV-PCR 
and HPV-ISH was available for 498 cases. 51/498 (10%) was high-risk HPV-positive338[Melchers 
et al. in preparation].
Immunohistochemistry
14 TMAs and 20 full sections were freshly cut and deparaffinized in xylene and rehydrated in 
a graded alcohol series. Antigen retrieval was performed by incubating for 15 minutes in EDTA 
(pH=8.0) at 100°C. After cooling endogenous peroxide was blocked by incubating in 0.3% per-
oxide solution. Slides were then incubated for one hour with the primary monoclonal antibody 
L8A4 (a kind gift from dr. Bigner, Duke University Medical Center, Durham, NC) at room temper-
ature in a concentration of 1:200, followed by 30 mins. incubation with horseradish peroxidase 
conjugated rabbit anti-mouse secondary antibody, and 30 mins. incubation with goat anti-rab-
bit horseradish conjugated tertiary antibody. Slides were developed with di-aminobenzidene 
chromogen solution, followed by haematoxylin counterstaining. In addition to the control tis-
sues included on the TMA slides, full sections of rt-PCR confirmed positive and negative GBM 
tissues were included.
Analysis of immunohistochemistry
All TMAs were independently scored by two of the authors (LJM. and MFM). Cases with dis-
cordant results were discussed until consensus was reached. Cases were excluded when no 
core with a representative amount of tumour cells was present. EGFRvIII was semi-quantita-
tively scored, assessing percentage of tumour cells with membranous staining and the inten-
sity of staining. Cases with >10% staining were considered ++, as described before459,460. Cases 
with staining in ≤10% but >0% were considered +. All ++ and + cases were considered positive. 
All other cases were considered negative.
rt-PCR
For the reverse-transcriptase-PCR (rt-PCR) assay, total RNA was extracted as described be-
fore461. In short, 2 to 4 10 µm sections of FFPE tissue were dissolved in xylene and tissue was 
rehydrated in serial ethanol dilutions. The pellet was dried, washed and resuspended in a Tris/
EDTA lysis buffer with proteinase K (Invitrogen, Carlsbad, CA) overnight at 60°C. RNA was 
We assessed the prevalence of EGFRvIII in three well defined cohorts of HNSCC: 1) a repre-
sentative cohort of oral squamous cell carcinomas (OSCC-cohort), which is the most common 
subgroup of HNSCC; 2) a complete cohort of oropharyngeal squamous cell carcinoma patients 
(OpSCC-cohort), who are frequently treated by cetuximab concurrently with radiotherapy and 
who may benefit from EGFRvIII specific therapy, and: 3) a cohort of HNSCC from various lo-
cations homogeneously treated by postoperative radiotherapy (POSTOP-cohort). All tumours 
were analyzed for the presence of EGFRvIII protein expression by immunohistochemistry. To 
confirm the presence or absence of EGFRvIII protein expression, we designed rt-PCR primers 
specifically for EGFRvIII RNA extracted from FFPE tissue.
Materials & methods
Patient selection
For this study, three separate patient cohorts of HNSCC were tested for the presence of EG-
FRvIII. The clinicopathological data of two of these series have been previously described in 
more detail338,370.
In short, the OSCC-cohort consists of resection tissues of 200 primary oral squamous cell car-
cinomas (ICD-O-3 locations 00.3-6.9 excluding C01.9). Cases were diagnosed between 1997 
and 2008 and treated in the UMC Groningen by surgical resection of the primary tumour and a 
therapeutic or elective neck dissection, without prior local or systemic oncological treatment370.
The OpSCC-cohort consists of pre-treatment biopsies and surgical resection tissues of 196 pri-
mary oropharyngeal squamous cell carcinomas (OpSCC) from the base-of-tongue and tonsil 
(ICD-O-3 locations C01.9 and C09, respectively), diagnosed from 1997 till 2012. All patients were 
curatively or palliatively treated in the UMC Groningen [Melchers et al. in preparation].
The POSTOP-cohort consists of resection tissue of 167 primary HNSCC from various sites, diag-
nosed between 1993 and 2003. These cases were uniformly treated with resection of the primary 
tumour and postoperative radiotherapy338. Eleven cases were also present in one of the other 
two cohorts and these overlapping cases were excluded from the POSTOP-cohort.
In total, these combined series of formalin-fixed paraffin-embedded (FFPE) HNSCC consisted of 
552 unique tumours. Cases were included on 14 tissue microarrays (TMAs) and 20 full sections 
of OpSCC cases that were considered too small to reliably include in TMA construction. TMAs 
were constructed as described before338,370. Fresh-frozen material was available for 21 OSCC and 
14 POSTOP cases.
Additionally, a group of nine FFPE biopsies of recurrent HNSCC after platinum-containing 
chemoradiation therapy for advanced stage OSCC (n=6) or OpSCC (n=3) was composed (data 
not shown).
As control group, four cases of FFPE GBM which were previously found EGFRvIII positive (n=3) 
or negative (n=1) were selected. Additionally, fresh-frozen tissue was available for one positive 
and the negative case. Cases from this control group were included as control for every immu-
nostaining and rt-PCR.







extracted by phenol/chloroform and eventually precipitated by isopropanol. For fresh-frozen 
tissue RNA of 4 to 6 10 µm sections was isolated using TRIzol (Invitrogen) according to the 
manufacturer’s protocol. Total RNA was then treated with DNase I (Ambion®-free Kit, Invitro-
gen) for 30 minutes at 37˚C and reverse transcribed using hexamer primers and Superscript II 
(Invitrogen) according to the manufacturer’s protocol.
20 ng (as measured directly after DNase treatment) of 1st strand cDNA was used as a template 
in a 30 µl PCR reaction containing 10xPE bufferII, 1 Unit Ampli-Taq Gold, 1.5 mM MgCl2 (Applied 
Biosystems, Foster City, CA), 0.9 µM of each primer and 0.2 mM dNTPs. PCR cycling param-
eters were: one cycle of 95°C for 10 min, 40 cycles of 95°C for 30s, Tannealing for 30s and 72°C for 
30s, followed by one cycle of 72°C for 7 min. The products were visualized on a 1.5% agarose 
gel containing ethidium bromide. 
Primersets to detect EGFRvIII and EGFRwt were designed to flank the deletion of exons 2-7 
with Clone Manager using the Ensembl sequence transcript ENST00000275493.
Primer sequences for EGFRwt were: 5’-TGCTGGCTGCGCTCTGC-3’ (located in exon 1), 
5’-GAACATCCTCTGGAGGCTGAGA-3’ (exon 2), resulting in a unique product for EGFRwt of 125 
bp. To detect EGFRvIII, 5’-TGCTGGCTGCGCTCTGC-3’ (exon 1), and 5’-CACAGGCTCGGACG-
CAC-3’ (exon 8) were used, generating products of 92 bp (for EGFRvIII) and 894 bp (for EG-
FRwt). Annealing temperature (Tannealing) for all primers was 62°C. The primerset reported by Sok 
et al.104 was used as control at 59°C annealing temperature. The quality of the cDNA was as-
sessed by performing rt-PCR for the housekeeping gene GAPDH : 5’-CCACATCGCTCAGACAC-
CAT-3’ and 5’-GCGCCCAATACGACCAAAT-3’ (amplicon size 67 bp) at an annealing temperature 
of 59°C.
Cases were considered positive for EGFRvIII when they were positive for immunohistochemical 
expression of EGFRvIII and also showed a product of the expected size in one of the EGFRvIII-
specific rt-PCRs.
Statistical analysis
Statistical analysis was performed with PASW Statistics 20.0 (IBM software, Armonk, NY). Cat-
egorical data were compared using the χ2-test. Tests were performed two-tailed. p<0.05 was 
considered statistically significant.
Results
To optimize the detection of EGFRvIII expression by immunohistochemistry with the L8A4 an-
tibody, the immunostaining was first performed on a control group of four FFPE cases of GBM. 
Three of four GBM had positive immunohistochemical expression (+ or ++ membranous ex-
pression) of EGFRvIII. Additionally weak cytoplasmic staining was visible in two of the positive 
cases (figure 9.1A). rt-PCR using our newly designed primersets revealed positive products in 
all three immunohistochemistry-positive cases, whereas in the GBM without EGFRvIII protein 
expression only EGFRwt was detected. Using the primers reported by Sok et al.104 we confirmed 
our rt-PCR results, although with PCR products of lower intensity (figure 9.1B). Fresh-frozen 
Table 9.1. Clinicopathological characteristics.
OSCC series OpSCC series HNSCC series Total
N (%) N (%) N (%) N (%)
Total patients 189 (100) 184 (100) 149 (100) 522 (100)
Sex
Male 111 (59) 119 (65) 98 (66) 328 (63)
Female 78 (41) 65 (35) 51 (34) 194 (37)
Age at diagnosis (years)
Median 63 57 60 60
Range 25-94 36-89 36-90 25-94
Primary tumour site
Oral cavity 189 (100) 83 (56) 272 (52)
Oropharynx 184 (100) 21 (14) 205 (39)
Hypopharynx 8 (5) 8 (2)
Larynx 37 (25) 37 (7)
cT status
1-2 131 (69) 78 (42) 45 (30) 254 (49)
3-4 58 (31) 106 (58) 104 (70) 268 (51)
cN status
0 126 (67) 31 (17) 69 (46) 226 (43)
+ 63 (33) 153 (83) 80 (54) 296 (57)
Primary tumour treatment
Resection 89 (47) 10 (5) 99 (19)
Resection+RT 100 (53) 29 (16) 149 (100) 278 (53)
RT 43 (23) 43 (8)
RT+CHT 68 (37) 68 (13)
Palliative 34 (19) 34 (7)
pT status
1-2 129 (68) 26 (67) 38 (26) 193 (51)
3-4 60 (32) 13 (33) 111 (74) 184 (49)
x 145 145
pN status
0 103 (55) 9 (19) 43 (32) 155 (42)
+ 86 (46) 39 (81) 90 (68) 215 (58)
x 136 16 152
High risk-HPV status n=176 n=182 n=140 n=498
Negative 175 (99) 135 (74) 137 (198) 447 (90)
Positive 1 (1) 47 (26) 3 (2) 51 (10)
Recurrence
No 147 (78) 137 (69) 119 (66) 372 (71)
Yes 42 (22) 57 (31) 62 (34) 150 (29)
Disease specific survival (months)
Estimated mean 119 92 76 91
95%CI 109-129 79-105 65-86 83-98
OSCC: oral squamous cell carcinoma; OpSCC: oropharyngeal squamous cell carcinoma; HNSCC: head-neck squamous cell carcinoma; 







our designed set as well as that reported by Sok et al.104. All 9 cases were positive for the EGFRwt 
(data not shown).
Because other studies in HNSCC report high EGFRvIII frequencies detected by immunohisto-
chemistry104,455, we tested whether this might be due to the conditions at which immunohis-
tochemistry was performed. Only one HNSCC study using the L8A4 antibody described the 
immunohistochemistry method used (a streptavidin-biotin detection method)455. Therefore we 
performed immunohistochemistry for the OSCC and HNSCC series (total n=338) again using 
RAMbio as second and avidin-biotin complex (Dako, Glostrup, Denmark) as third step. Moreo-
ver because tissue sections are generally stored and often used up to several months after cut-
ting, we used sections that were not freshly cut. Using this method, no positive membranous 
expression was observed. However, 9/189 (5%) OSCC and 19/149 (13%) HNSCC now showed a 
tumour cell-specific cytoplasmic staining in >10% of tumour cells (supplementary data S9.1). 
All 28 cases that displayed this staining pattern were subjected to rt-PCR by our primersets. 
33 negative staining cases were also included in the rt-PCR (total n=61). In none of these 61 pa-
tients expression of EGFRvIII was observed, while 49/61 (80%) were positive for EGFRwt (data 
not shown), confirming that RNA extracted from these samples was of sufficient quality to de-
tect EGFRvIII expression. Using the primers reported by Sok et al.104 also no EGFRvIII expres-
sion was observed. With the avidin-biotin immunostaining method the four GBM control cases 
material was available for one positive and the negative case, and analysis provided the same 
results (figure 9.1B). To test the analytical sensitivity of our rt-PCR, we performed rt-PCR on se-
rial dilutions of FFPE material of a GBM case that was both EGFRwt and EGFRvIII positive. Both 
transcripts were detectable diluting RNA at least 3125 times (up to approximately 0.006 ng; 
figure 9.2).
 
Next, expression of EGFRvIII, as determined by immunohistochemistry using the L8A4 anti-
body was assessed on 189 OSCC and 184 OpSCC (table 9.1). No case with + or ++ immunohisto-
chemical expression was identified.
Because some of the highest percentages of EGFRvIII have been reported in advanced stage 
and recurrent HNSCC454,455,457, we subsequently tested the group of 149 mainly advanced-stage 
HNSCC of the POSTOP-cohort (table 9.1). Again, immunohistochemistry did not identify any 
positive case. Finally a group of 9 FFPE biopsies of recurrent HNSCC after chemoradiation ther-
apy was tested both by immunohistochemistry and rt-PCR. All of these 9 recurrent cases were 
negative for both EGFRvIII immunohistochemistry and EGFRvIII rt-PCR as assessed by both 
Figure 9.1. EGFRvIII expression in four GBM controls A. EGFRvIII immunohistochemistry with the 
L8A4 antibody. Case 1: negative, case 2: +, case 3: ++, case 4: +. B. rt-PCR results on FFPE material 
(case 1-4) and fresh-frozen material (case 1 and 2 only). 
In fresh-frozen material of case 1 both EGFRvIII-specific primersets resulted in a 894 bp product which 
included exons 2-7, representing EGFRwt transcript.
Figure 9.2. Serial dilutions of positive GBM number 3 (figure 9.1A and 9.1B), showing detection of both 








showed a lightly increased cytoplasmic staining in addition to the membranous staining that 
was also present with the RAMpo-GARpo immunostaining (supplementary data S9.1).
Additionally, we performed rt-PCR on 21 OSCC and 14 HNSCC cases for which fresh-frozen ma-
terial was available. All 35 cases were negative for EGFRvIII immunoexpression in the corre-
sponding FFPE slides. 10/35 cases had also been tested negative by rt-PCR on FFPE material. 
Rt-PCR with our primersets revealed no cases expressing the EGFRvIII transcript in this fresh-
frozen material. 34/35 (97%) were positive for the EGFRwt transcript.
Discussion
This study analyzed 531 head-neck squamous cell carcinomas for the presence of the EGFRvIII 
mutation. Immunohistochemistry using the L8A4 antibody revealed that none of the 531 cases 
expressed EGFRvIII. Because this was in contrast with two previous studies that used the L8A4 
antibody on HNSCC cases, we also performed rt-PCR for EGFRvIII with primers optimized for 
FFPE material. Rt-PCR confirmed the absence of EGFRvIII in all of the 70 FFPE cases tested and 
all of the 35 fresh-frozen cases tested (total 95 unique cases). Moreover, we showed that the 
immunohistochemistry conditions may greatly influence the specificity of the L8A4 antibody.
EGFRvIII is a promising target for specific therapy for several reasons. It is not expressed in 
normal tissues, its biology has been extensively described, and the presence of this specific mu-
tation confers increased proliferation and resistance to platinum containing chemotherapy and 
radiotherapy in vitro104,449. Because of the well established expression in 20-30% of GBM several 
trials on EGFRvIII-specific therapeutics in patients with GBM are currently in progress446.
In HNSCC however, the reported rates of EGFRvIII expression vary widely (0-80%). Today, nine 
studies have assessed the prevalence of EGFRvIII in HNSCC (table 9.2). The average sample 
size in these nine studies was only 44 cases. Although patient selection criteria were not always 
clearly described, most head-neck tumour sites and stages are included in these studies. All 
studies used a single detection technique; either rt-PCR (n=6), or immunohistochemistry (n=3). 
Because most rt-PCR based studies used primersets that were optimized for fresh-frozen mate-
rial, for the current study we designed our own primerset to perform optimally on FFPE tissue. 
Validation was performed on GBM tissue that showed positive L8A4 immunohistochemistry 
and rt-PCR using published primers104.
It has been well described that cases with the EGFRvIII transcript detected by rt-PCR do not al-
ways express the associated protein. This is not only a problem in HNSCC104,455, but in all tumour 
types446. The reverse, positive immunohistochemical expression without detection of the mRNA 
transcript, has also been reported104,446,455. Because of the discordance between both methods, 
a combined approach, detecting protein and mRNA has been proposed, with cases considered 
EGFRvIII only when both assays yield positive results446. 
This combined approach was used in the current study. None of the previous studies in HNSCC 
used a combined approach. However, two of the immunohistochemical studies in HNSCC did 















































































































































































































































































































































































































































































































































































































































































































































































































































































































In summary, we analyzed the presence of the EGFRvIII mutation in a total number of 531 HN-
SCC by immunohistochemistry and rt-PCR with FFPE optimized primers. None of the HNSCC 
cases expressed EGFRvIII. Therefore EGFRvIII is not part of the malignant phenotype in these 
tumours and does not influence the response to EGFR-targeted therapy in HNSCC. It is there-
fore not a usable clinical prognostic marker.
Funding: This work was partly funded by the CTMM Air Force consortium (http://www.ctmm.nl). 
CTMM pays for the salaries of MJAMC and MFM (partly) and had no role in study design, data 
collection and analysis, decision to publish and preparation of the manuscript.
rt-PCR. Only one of those 3 cases was rt-PCR positive104. In the other study 37 cases were L8A4-
positive, of which 4 were subjected to rt-PCR, with three of those positive for the transcript. 
Interestingly, using the EGFRvIII primers, a PCR product was also found in one of 4 tested L8A4-
negative cases455. One explanation for this is the occurrence of aspecific (non-related) EGFRvIII 
variants. However, no sequencing data was presented to confirm the specificity455. One study 
that used sequence analysis of rt-PCR products did not detect the EGFRvIII variant in 82 HN-
SCC cases452, which is in very good agreement with our data.
Using the combined approach, we were able to screen a large number of HNSCC, using the L8A4 
antibody, followed by rt-PCR of the L8A4-positive cases. In total we performed immunohisto-
chemistry on 531 unique HNSCC cases and rt-PCR on 95 of these. Immunohistochemistry was 
performed on TMAs, but did not show any positive staining in the HNSCC cases. Indeed, even 
staining of less than 10% of tumour cells (below our criterion for positive expression) was not 
observed. Because several cores were taken from the tumour blocks, it could be hypothesized 
that a heterogeneously expressed protein will not be detected in all cases on TMA. To check 
the homogeneity of immunoexpression we additionally immunostained 20 full FFPE sections of 
OpSCC cases, which were homogeneously negative. Also in literature, EGFRvIII, as detected by 
the L8A4 antibody in HNSCC, is reported to be homogeneously expressed104,455. Moreover, us-
ing the same immunohistochemistry protocol 130 primary GBM were recently tested in our lab. 
24/130 (18%) were considered positive for membranous expression [Conroy et al., manuscript in 
preparation], in good agreement with the expected prevalence in GBM446.
To test the influence of the immunohistochemistry protocol, we performed the L8A4 staining 
again using a different protocol also used in many labs on older TMA slides. This resulted in 
cytoplasmic immunostaining in 28/338 cases (8%). Because cytoplasmic expression of EGFRvI-
II has been described by others460,462,463, we performed rt-PCR on the cases with cytoplasmic 
staining. No case was found positive for the EGFRvIII mRNA transcript. Cytoplasmic EGFRvIII 
expression was also not associated with mRNA expression in fresh- frozen breast cancer tis-
sue463. Because the observed cytoplasmic staining was not associated with mRNA expression, 
we considered this an artefact of this specific staining protocol. Because it seems to be tumour 
cell-specific staining, it might explain some of the high rates of EGFRvIII expression that are 
reported in HNSCC.
 
HNSCC is not the only tumour type where EGFRvIII is not expressed. Ovarian459,464, colorectal 
carcinomas451,465,466 and lung adenocarcinomas451,467-469 have generally been found negative in mul-
tiple studies using various techniques. The clinical implications of the absence of EGFRvIII in 
HNSCC are that there is currently no reason to set up EGFRvIII-specific clinical trials in HNSCC. 
The lack of EGFRvIII expression in HNSCC also implies that the response or resistance to chemo-
therapy, radiotherapy and EGFR-targeted therapy is not influenced by the presence of EGFRvIII 







A. example of a negative case immunostained by the RAMpo-GARpo method on a freshly cut slide. B. ex-
ample of the same core showing cytoplasmic staining for EGFRvIII immunostained by the avidin-biotin 
method on an older slide. C. Higher magnification of A. D. Higher magnification of B. E. Control glioblas-
toma 3 immunostained by the RAMpo-GARpo method on a freshly cut slide. F. Control glioblastoma 3 
immunostained by the avidin-biotin method on an older slide.
SuPPleMentARy dAtA S9
Supplementary data S9.1.
